AU2020233456A1 - Method for preparing influenza HA split vaccine - Google Patents

Method for preparing influenza HA split vaccine Download PDF

Info

Publication number
AU2020233456A1
AU2020233456A1 AU2020233456A AU2020233456A AU2020233456A1 AU 2020233456 A1 AU2020233456 A1 AU 2020233456A1 AU 2020233456 A AU2020233456 A AU 2020233456A AU 2020233456 A AU2020233456 A AU 2020233456A AU 2020233456 A1 AU2020233456 A1 AU 2020233456A1
Authority
AU
Australia
Prior art keywords
influenza
split vaccine
vaccine
split
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020233456A
Other languages
English (en)
Inventor
Yu Adachi
Manabu ATO
Yoshimasa Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Infectious Diseases
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
National Institute of Infectious Diseases
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd, National Institute of Infectious Diseases, Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Publication of AU2020233456A1 publication Critical patent/AU2020233456A1/en
Assigned to JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES, Sumitomo Pharma Co., Ltd. reassignment JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES Amend patent request/document other than specification (104) Assignors: JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES, SUMITOMO DAINIPPON PHARMA CO., LTD.
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2020233456A 2019-03-04 2020-03-03 Method for preparing influenza HA split vaccine Pending AU2020233456A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019038662 2019-03-04
JP2019-038662 2019-03-04
PCT/JP2020/008974 WO2020179797A1 (ja) 2019-03-04 2020-03-03 インフルエンザｈａスプリットワクチンの製造方法

Publications (1)

Publication Number Publication Date
AU2020233456A1 true AU2020233456A1 (en) 2021-10-07

Family

ID=72337458

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020233456A Pending AU2020233456A1 (en) 2019-03-04 2020-03-03 Method for preparing influenza HA split vaccine

Country Status (15)

Country Link
US (1) US12491240B2 (enExample)
EP (1) EP3936147A4 (enExample)
JP (1) JP7545955B2 (enExample)
KR (1) KR20210135261A (enExample)
CN (1) CN114096273A (enExample)
AU (1) AU2020233456A1 (enExample)
BR (1) BR112021017310A8 (enExample)
CA (1) CA3132578A1 (enExample)
EA (1) EA202192398A1 (enExample)
IL (1) IL285984A (enExample)
MX (1) MX2021010685A (enExample)
MY (1) MY208974A (enExample)
PH (1) PH12021552094A1 (enExample)
SG (1) SG11202109566XA (enExample)
WO (1) WO2020179797A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12059462B2 (en) 2018-07-23 2024-08-13 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
EP4054630A2 (en) * 2019-11-07 2022-09-14 Seqirus UK Limited Compositions and methods for producing a viral vaccine with reduced particle size
AU2024264265A1 (en) * 2023-04-26 2025-11-13 Japan Institute For Health Security Anti-influenza antibody

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374894B1 (en) * 1993-09-13 2014-09-17 Protein Sciences Corporation A method for producing influenza hemagglutinin multivalent vaccines
US8278083B2 (en) 2004-03-22 2012-10-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inactivated influenza virus compositions
US20230201329A1 (en) * 2006-07-17 2023-06-29 Glaxosmithkline Biologicals Sa Influenza vaccine
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8044056B2 (en) 2007-03-20 2011-10-25 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
BRPI0911699B8 (pt) 2008-07-25 2023-02-28 Inst Res Biomedicine vetor, célula, composição farmacêutica, uso de um anticorpo, ou fragmento de ligação a antígeno deste
WO2010047509A2 (ko) 2008-10-24 2010-04-29 아주대학교 산학협력단 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물
US8883479B2 (en) * 2008-11-25 2014-11-11 Baxter Healthcare Sa Method for production of pH stable enveloped viruses
CN101524538A (zh) 2009-03-26 2009-09-09 成都康华生物制品有限公司 一种流感-大流行流感二价联合疫苗及其制备方法
JP2013520172A (ja) 2010-02-18 2013-06-06 モウント シナイ スクール オフ メディシネ インフルエンザウイルス疾患の予防及び治療で用いるためのワクチン
MX338758B (es) 2010-03-08 2016-04-29 Celltrion Inc Anticuerpos monoclonales humanos, derivados de celulas b humanas, y que tienen actividad neutralizante contra el virus de la influenza a.
AU2011235220B2 (en) 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
KR101960928B1 (ko) 2011-04-21 2019-07-17 올로지 바이오서비시즈, 인크. 백신으로부터 항원을 단리하고 정량하기 위한 방법
CN102406931B (zh) * 2011-11-25 2014-02-05 成都康华生物制品有限公司 大流行流感病毒裂解疫苗
US20150098966A1 (en) * 2012-05-16 2015-04-09 Kj Biosciences Llc Influenza vaccines
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
CN106794241A (zh) 2014-08-18 2017-05-31 圣诺菲·帕斯图尔公司 烷基化流感疫苗
SG11201705264WA (en) 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
WO2016178811A1 (en) * 2015-05-04 2016-11-10 Epivax, Inc. Modified h7 hemagluttinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence
CN108348618B (zh) * 2015-09-29 2021-06-15 大日本住友制药株式会社 腺嘌呤缀合物化合物及其作为疫苗佐剂的用途
US11253476B2 (en) * 2017-03-29 2022-02-22 Sumitomo Dainippon Pharma Co., Ltd. Vaccine adjuvant formulation
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
US12059462B2 (en) * 2018-07-23 2024-08-13 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
US20220072126A1 (en) * 2018-12-26 2022-03-10 Sumitomo Dainippon Pharma Co., Ltd. Preparation including vaccine adjuvant
EP3930750A4 (en) * 2019-02-28 2023-01-18 Novavax, Inc. PROCEDURES TO PREVENT DISEASE OR DISORDER FROM RSV INFECTION

Also Published As

Publication number Publication date
EA202192398A1 (ru) 2021-11-23
CA3132578A1 (en) 2020-09-10
MY208974A (en) 2025-06-14
KR20210135261A (ko) 2021-11-12
MX2021010685A (es) 2021-12-10
IL285984A (en) 2021-10-31
EP3936147A1 (en) 2022-01-12
EP3936147A4 (en) 2022-09-28
US12491240B2 (en) 2025-12-09
PH12021552094A1 (en) 2022-05-30
BR112021017310A2 (enExample) 2021-11-16
WO2020179797A1 (ja) 2020-09-10
BR112021017310A8 (pt) 2022-12-06
JPWO2020179797A1 (enExample) 2020-09-10
SG11202109566XA (en) 2021-10-28
US20220152191A1 (en) 2022-05-19
CN114096273A (zh) 2022-02-25
JP7545955B2 (ja) 2024-09-05

Similar Documents

Publication Publication Date Title
AU570929B2 (en) Broad spectrum influenza antisera
US4625015A (en) Broad spectrum influenza antisera
US11732031B2 (en) Method for producing influenza HA split vaccine
CN105452270A (zh) 流行性感冒病毒疫苗及其用途
US12491240B2 (en) Method for producing influenza HA split vaccine
JP7762643B2 (ja) 免疫原性組成物
CN101227919B (zh) 基于肽的流感疫苗制剂
US8883165B2 (en) Modified peptide vaccine derived from influenza M2
US20230406910A1 (en) Method for producing influenza ha split vaccine
WO2009152518A1 (en) Novel peptide adjuvant for influenza vaccination
TWI857017B (zh) 流感ha裂解疫苗之製造方法
HK40068192A (en) Method for preparing influenza ha split vaccine
EA045912B1 (ru) Способ приготовления сплит-вакцины на основе гемагглютинина гриппа
CN114106204A (zh) 一种具有多种甲型流感病毒免疫原性的融合蛋白及其制备与应用
HK40032891A (en) Method for producing influenza ha split vaccine
EA045852B1 (ru) Способ получения сплит-вакцины с ha гриппа
WO2010146848A1 (en) An antigenic peptide derived from influenza virus and a method for selecting anti-influenza virus antibody
JP2023515829A (ja) 小児対象のための高用量インフルエンザワクチン

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES

Free format text: FORMER NAME(S): SUMITOMO DAINIPPON PHARMA CO., LTD.; JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES

Owner name: SUMITOMO PHARMA CO., LTD.

Free format text: FORMER NAME(S): SUMITOMO DAINIPPON PHARMA CO., LTD.; JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES